SCHEMBL252987

SCHEMBL252987

CCCC[C@@H](O)[C@H](O)c1c(Cl)cccc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
CSNK1E P49674 1/20 0.37
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.35
DRD3 P35462 3/20 0.35
CTSK P43235 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
TAS1R2 Q8TE23 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP3A4 P08684 2/20 0.33
DRD2 P14416 2/20 0.33
POLB P06746 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL253315 1.00 MEN1 (0.39) MEN1KMT2ACSNK1EALDH1A1KDM4E
SCHEMBL253314 1.00 MEN1 (0.39) MEN1KMT2ACSNK1EALDH1A1KDM4E
SCHEMBL252988 1.00 MEN1 (0.39) MEN1KMT2ACSNK1EALDH1A1KDM4E
SCHEMBL252530 1.00 MEN1 (0.39) MEN1KMT2ACSNK1EALDH1A1KDM4E
SCHEMBL16064835 0.90 MEN1 (0.36) MEN1KMT2ACSNK1EALDH1A1KDM4E
SCHEMBL252916 0.83 TAS1R3 (0.39) MEN1KMT2AALDH1A1DRD3TAS1R3
SCHEMBL253180 0.83 TAS1R3 (0.39) MEN1KMT2AALDH1A1DRD3TAS1R3
SCHEMBL252915 0.83 TAS1R3 (0.39) MEN1KMT2AALDH1A1DRD3TAS1R3
SCHEMBL252914 0.83 TAS1R3 (0.39) MEN1KMT2AALDH1A1DRD3TAS1R3
SCHEMBL253181 0.83 TAS1R3 (0.39) MEN1KMT2AALDH1A1DRD3TAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423433-B1 SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES BIO PHARM SOLUTIONS CO LTD (KR) 2025-12-17 EP disclosed
EP-2970112-B1 PHENYL CARBAMATE COMPOUND AND A COMPOSITION FOR PREVENTING OR TREATING A MEMORY LOSS-RELATED DISEASE COMPRISING THE SAME BIO PHARM SOLUTIONS CO LTD (KR) 2025-03-12 EP disclosed
EP-2968210-B1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY BIO PHARM SOLUTIONS CO LTD (KR) 2024-09-11 EP disclosed
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease BIO-PHARM SOLUTIONS CO., LTD. (KR) 2024-03-19 US disclosed
CN-111419830-B Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epileptic related syndromes 比皮艾思药物研发有限公司 2024-01-30 CN disclosed
EP-4204395-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE Bio-Pharm Solutions Co., Ltd. (KR) 2023-07-05 EP disclosed
CN-115996905-A Phenylalkyl carbamate compounds for use in preventing or treating neurodegenerative diseases 生物药品解决方案有限公司 2023-04-21 CN disclosed
CN-109939092-B Phenyl carbamate compounds for use in preventing or treating pediatric epilepsy and epilepsy-related syndrome 比皮艾思药物研发有限公司 2022-03-22 CN disclosed
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-01-03 US disclosed
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-01-03 US disclosed
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-01-03 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
WO-2012096458-A2 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 WO disclosed
WO-2012096458-A2 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 WO disclosed
WO-2012002773-A2 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-01-05 WO disclosed
WO-2012002773-A2 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME CPT1B, MYLK, PYGM MEN1 3930/4885KMT2A 940/4885CSNK1E 1627/4885
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease SNCA, MAPT, CHAT MEN1 4859/4885KMT2A 1213/4885CSNK1E 1622/4885
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES CPS1, BCHE, ACHE MEN1 2482/4885KMT2A 507/4885CSNK1E 2613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.